Parkinson's disease pscyhosis schizophrenia
Conditions
Interventions
neuromelanin
Parkinson
schizophrenia
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Patients with schizofrenia/psycosis: * clinical diagnosis schizophrenia or schizophreniphorm disorder or psychotic episode;Patients with Parkinson's disease * clinical diagnosis Parkinson's disease, strong indication of Parkinson's disease or Parkinsonian symptoms;Healthy controls: * age- and gender matched with patients at group level;All participants: * Capacity to understand the study and to sign *informed consent*.
Exclusion criteria
Exclusion criteria: Healthy controls: * Severe neurologic and psychiatric disorders * Use of psychotropic drugs or drugs of abuse that may influence the dopamine system;All participants: - contra-indications for MRI (including pacemaker, ferromagnetic implants, possibility of iron splinters in the orbita, claustrophobia ) - pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference between patients and healthy controls in neuromelanin concentration (or indirect quantitative measure or this) in the substantia nigra and locus coeruleus. | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlations between neuromelanin concentrations (or indirect quantitative measure or this) in the substantia nigra or locus coeruleus and therapy resistance or side effects of therapy (such as extrapyramidal symptoms). | — |
Countries
The Netherlands
Outcome results
None listed